- FY NET LOSS ATTRIBUTABLE A$14.3 MILLION VERSUS LOSS A$5.4 MILLION
- FY REVENUE FROM ORDINARY ACTIVITIES A$2 MILLION VERSUS A$7.8 MILLION
CYP finding out just how expensive it is to run trials by the looks .... @bedger they might scrape through if they get the oppies in the money but I am predicting they will undertake another CR before that - it won't take long for the GVHD trial in the USA to start to absorb what little cash they have left
News: CYP Cynata Therapeutics Posts FY Net Loss Attributable Of A$14.3 Million, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 16.0¢ | $1.021K | 6.379K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 77738 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 3400 | 1 |
View Market Depth
| Last trade - 09.59am 24/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |